Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat Maintenance in Multiple Myeloma Post-Autologous HCT
NCT02722941Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in multiple myeloma (MM), sponsored by Moffitt Cancer Center. Started Jun 2016; status: completed.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02722941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722941.